Greater London, England
Benefits and relocation
over 1 year ago
Director will lead a new Department of Insulin Resistance at new Research Centre based in England.
This Transformational Research Unit will focus on early stage research and innovation in the treatment of type 2 diabetes and other cardio metabolic diseases.
The main focus for the new Department of Insulin Resistance will be the discovery, validation and early pipeline progression of innovative first in class insulin resistance and broadly related MOA targets (for example in adipose, muscle and/or liver tissue).
The scope of the research is broad and you will be expected to use creativity and strategic judgement to realise the scientific goals with considerable autonomy.
As Director, you will be building and leading a state-of-the-art Department of Insulin Resistance recognised worldwide for its innovative approach to research with specific focus on first-in-class targets that have strong transnational evidence. You will hold the day-to-day managerial responsibility of the department's employees, as well as define and setting the strategic direction for research in Insulin Resistance, aligned with the targets and priorities set the board
The role will be reporting to Site Head and will be a part of the senior site management team.
To apply for this role you will be meeting following requirements-
Qualifications and experience:
Minimum PhD and/or MD, or equivalent;
Significant post-doctoral experience in the field of biology and insulin;
Experience in pharmaceutical targeted discovery in human-centric academic science is a prerequisite;
Track of success in achieving recognised result in in-vitro research projects;
Leadership capabilities and line management experience will be highly preferred;
Innovative, open to new ideas and have a forward-looking strategic mindset;
A strong communicator with solid presentation and English skills;
Adaptable and striving in a highly dynamic, professional and challenging environment.